TSXV - Delayed Quote CAD

LSL Pharma Group Inc. (LSL.V)

0.3900

0.0000

(0.00%)

At close: 12:48:26 PM EDT

TSX Penny Stocks: 3 Picks With Market Caps Under CA$70M

The Canadian market has shown resilience, with the TSX only 4% off its record high, buoyed by a strong performance in the materials sector. In such a climate, investors might consider exploring penny stocks—smaller or newer companies that offer potential growth at lower price points. Despite being an older term, penny stocks can still provide valuable opportunities when they possess robust financials and clear growth trajectories.

Simply Wall St. 3 hours ago

LSL.V
0.00%

DMXCF

ALXPF
LSL PHARMA GROUP REPORTS ITS FOURTH QUARTER AND YEAR-END 2024 RESULTS

LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma "), a Canadian integrated pharmaceutical company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2024 ("Q4-24" and "FY-24"). All amounts are presented in millions of Canadian dollars.

CNW Group yesterday

LSL.V
0.00%
LSL PHARMA GROUP INC. ANNOUNCES ITS PARTICIPATION IN THE "2025 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE"

LSL PHARMA GROUP INC. (TSXV: LSL) (TSXV: LSL.DB) (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, announced today it will participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference. Mr. Roberge, President and CEO, will make a presentation on May 5 at 10:30 EST, and will be available for one-on-one meetings throughout the conference.

CNW Group 3 days ago

LSL.V
0.00%
LSL PHARMA GROUP ANNOUNCES THE SEMI-ANNUAL INTEREST PAYMENT ON THE CONVERTIBLE DEBENTURES LISTED AS LSL.DB

LSL PHARMA GROUP INC (TSXV: LSL) (TSXV: LSL.DB) (the "Company" or "LSL Pharma"), a Canadian integrated pharmaceutical company reports that the semi-annual interest payment (the "Interest Payment") on its outstanding Unsecured Convertible Debentures (the "Debentures") listed on the TSXV under symbol "LSL.DB" will be made on April 30, 2025. The record date for the payment of interest on the Debentures is April 21, 2025. The Corporation will pay to each Debenture holder of record an amount of $54.5

CNW Group 9 days ago

LSL.V
0.00%
LSL PHARMA GROUP ANNOUNCES THE SIGNING OF TWO AGREEMENTS TO MARKET NEW OPHTHALMIC PRODUCTS IN CANADA

GROUPE LSL PHARMA INC (TSXV: LSL) (TSXV: LSL.DB) (the "Company" or "LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to announce the signing of two new agreements to market six (6) to ten (10) sterile eye drops for the prescription market in Canada.

CNW Group 29 days ago

LSL.NE

LSL.V
0.00%
LSL PHARMA GROUP APPOINTS LOUIS LAFLAMME TO THE BOARD OF DIRECTORS

LSL PHARMA GROUP INC. (TSXV: LSL) (TSXV: LSL.DB) (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to announce the appointment of Louis Laflamme as a member of the board of directors.

CNW Group last month

LSL.NE

LSL.V
0.00%
LSL PHARMA GROUP GRANTS SHARE OPTIONS

LSL PHARMA GROUP INC. (TSXV: LSL) (TSXV: LSL.DB) ("the Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, announced that it has granted an aggregate of 625,000 share options (each, an "Option") to three new officers and employees of the Corporation in accordance with the Corporation's share option plan.

CNW Group 3 months ago

LSL.V
0.00%
LSL PHARMA GROUP EXPANDS ITS ACTIVITIES BY AQUIRING DERMOLAB PHARMA AND ANNOUNCES THE CLOSING OF A CONCURRENT DEBT FINANCING

LSL PHARMA GROUP INC. (TSXV: LSL, LSL.DB) ("the Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical Corporation, is pleased to announce the acquisition of Dermolab Pharma Ltd. ("Dermolab"), a contract manufacturing company specializing in the manufacturing of liquid, and semi-solid products, based in Ste-Julie, Quebec. This acquisition increases LSL Pharma's contract development and manufacturing activities, while creating synergies with its other subsidiaries, LSL Laboratory Inc

CNW Group 4 months ago

LSL.V
0.00%
LSL PHARMA GROUP ANNOUNCES STRONG FISCAL Q3-24 RESULTS AND $2.4 MILLION DEBT FINANCINGS TO SUPPORT ITS GROWTH INITIATIVES

LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma "), a Canadian integrated pharmaceutical company, today reported its financial and operating results for the three- and nine-month periods ended on September 30, 2024.

CNW Group 5 months ago

LSL.V
0.00%
LSL PHARMA GROUP ANNONCES $1.4 MILLION OF NEW ORDERS FROM INTERNATIONAL CLIENTS AND COMPLETION OF STERI-MED PHARMA'S PHASE 1 PRODUCTION SCALE UP

LSL PHARMA GROUP INC. (TSXV: LSL) , (TSXV: LSL.DB) ("LSL Pharma" or the "Corporation"), an integrated Canadian-based pharmaceutical company, announces having secured $1.4 million on new orders from international clients, as well as having completed the initial phase of production scale-up at its Steri-Med Pharma ("Steri-Med") plan. The initial phase of production scale up has contributed to more than double the plant capacity compared to 2023 levels, and enabled Steri-Med to win new internationa

CNW Group 5 months ago

LSL.V
0.00%
LSL PHARMA GROUP ANNOUNCES THE FIRST INTEREST PAYMENT ON THE CONVERTIBLE DEBENTURES LISTED AS LSL.DB

LSL PHARMA GROUP INC. (TSXV: LSL) ("LSL Pharma" or the "Corporation"), an integrated Canadian-based pharmaceutical company, reports that it will make on October 31, 2024, the first interest payment (the "Interest Payment") on its outstanding Unsecured Redeemable Debentures (the "Debentures") listed on the TSXV under symbol "LSL.DB". The Corporation will pay to each Debenture holder an amount of $113.025 per $1,000 principal amount of Debentures which represents accrued interest payable from Nove

CNW Group 6 months ago

LSL.V
0.00%
LSL PHARMA GROUP ANNOUNCES CHANGE OF AUDITORS AND GRANT OF OPTIONS

LSL PHARMA GROUP INC. (TSXV: LSL) ("LSL Pharma" or the "Corporation"), an integrated Canadian-based pharmaceutical Corporation, today announced a change of auditor from KPMG LLP (the "Predecessor Auditor") to Audacie Inc. (the "Successor Auditor").

CNW Group 7 months ago

LSL.V
0.00%
LSL Pharma Group Second Quarter 2024 Earnings: CA$0.007 loss per share (vs CA$0.038 loss in 2Q 2023)

LSL Pharma Group ( CVE:LSL ) Second Quarter 2024 Results Key Financial Results Revenue: CA$4.19m (up 106% from 2Q...

Simply Wall St. 7 months ago

LSL.V
0.00%
LSL PHARMA GROUP REPORTS RECORD REVENUES FOR THE SECOND QUARTER 2024

LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma "), a Canadian integrated pharmaceutical company, today reported its financial and operating results for the three- and six-months periods ended on June 30, 2024.

CNW Group 8 months ago

LSL.V
0.00%
LSL Pharma Group Announces Closing of Second and Final Tranche of Private Placement and Closing of Units for Debt

BOUCHERVILLE, Quebec, July 15, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma "), a Canadian integrated pharmaceutical company, is pleased to announce that it closed on July 12, 2024, the second and last tranche of a non-brokered private placement (the “Financing”) consisting of 2,400,000 units (each, a “Unit”) at a price of $0.40 per Unit for total gross proceeds of $960,000. Each Unit consists of one class A share of the Corporation (a “Common Shar

GlobeNewswire 9 months ago

LSL.V
0.00%
LSL Pharma Group Announces Voting Results of Its Annual and Special Meeting of Shareholders

BOUCHERVILLE, Québec, June 28, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL, LSL.DB) (“the Company” or “LSL Pharma”), a Canadian integrated pharmaceutical company, is pleased to announce the results of its annual and special meeting of shareholders held today in Montréal, Québec (the “Meeting”). The shareholders approved, by a majority of votes, resolutions to elect each of the following directors: Diane Beaudry Frank J. DellaFera Stuart W. Fowler Pierre LafrenièreMario Paradis Fran

GlobeNewswire 9 months ago

LSL.V
0.00%
LSL Pharma Group Secures $1.5 Million as the First Closing of Its Non-Brokered Private Placement

BOUCHERVILLE, Quebec, June 27, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL, LSL.DB) (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, announced that it has met the closing conditions of a non-brokered private placement for $1,5 million representing the first closing of the private placement financing announced on June 5, 2024 (the “Financing”). Pursuant to the Financing, the Corporation has issued 3,727,000 units (the “Units”) at a price of $0.40 pe

GlobeNewswire 9 months ago

LSL.V
0.00%
LSL Pharma Group Completes the Acquisition of Virage Santé

BOUCHERVILLE, Québec, June 18, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL) ("the Company" or "LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to announce the completion of the acquisition of Virage Santé ("Virage"), a company specializing in the manufacturing and marketing of natural health products ("NHPs"), based in Lévis, Quebec. This acquisition increases LSL Pharma's contract development and manufacturing activities, while creating synergies with its su

GlobeNewswire 10 months ago

LSL.V
0.00%
LSL Pharma Group Announces Engagement of Red Cloud Securities

BOUCHERVILLE, Quebec, June 11, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma "), a Canadian integrated pharmaceutical company, announces that, subject to regulatory approval, it has retained, effective June 10, 2024, Red Cloud Securities (“Red Cloud”) to provide market stability and liquidity services to the Corporation in compliance with the policies and guidelines of the TSX Venture Exchange (“TSX-V”) and other applicable legislation. Red Cloud is

GlobeNewswire 10 months ago

LSL.V
0.00%
LSL Pharma Group Announces a Combination of Private Placements for Maximum Aggregate Gross Proceeds of $4.5 Million

Up to $3.0 M in cash proceedsUp to $1.5 M in debts conversion BOUCHERVILLE, Quebec, June 05, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma "), a Canadian integrated pharmaceutical company, today announced the launch of a non-brokered private placement financing of Units (as defined hereinafter) of a maximum of $3.0 million (7.5 million Units) (the “Financing”) and that it is conducting discussions with its creditors to settle debts in Units for an a

GlobeNewswire 10 months ago

LSL.V
0.00%

Performance Overview

Return	LSL.V	S&P/TSX Composite index (^GSPTSE)
YTD	+6.85%	+1.67%
1-Year	-7.14%	+14.70%
3-Year	-46.58%	+20.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

LSL Pharma Group Inc. (LSL.V)

TSX Penny Stocks: 3 Picks With Market Caps Under CA$70M

LSL PHARMA GROUP REPORTS ITS FOURTH QUARTER AND YEAR-END 2024 RESULTS

LSL PHARMA GROUP INC. ANNOUNCES ITS PARTICIPATION IN THE "2025 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE"

LSL PHARMA GROUP ANNOUNCES THE SEMI-ANNUAL INTEREST PAYMENT ON THE CONVERTIBLE DEBENTURES LISTED AS LSL.DB

LSL PHARMA GROUP ANNOUNCES THE SIGNING OF TWO AGREEMENTS TO MARKET NEW OPHTHALMIC PRODUCTS IN CANADA

LSL PHARMA GROUP APPOINTS LOUIS LAFLAMME TO THE BOARD OF DIRECTORS

LSL PHARMA GROUP GRANTS SHARE OPTIONS

LSL PHARMA GROUP EXPANDS ITS ACTIVITIES BY AQUIRING DERMOLAB PHARMA AND ANNOUNCES THE CLOSING OF A CONCURRENT DEBT FINANCING

LSL PHARMA GROUP ANNOUNCES STRONG FISCAL Q3-24 RESULTS AND $2.4 MILLION DEBT FINANCINGS TO SUPPORT ITS GROWTH INITIATIVES

LSL PHARMA GROUP ANNONCES $1.4 MILLION OF NEW ORDERS FROM INTERNATIONAL CLIENTS AND COMPLETION OF STERI-MED PHARMA'S PHASE 1 PRODUCTION SCALE UP

LSL PHARMA GROUP ANNOUNCES THE FIRST INTEREST PAYMENT ON THE CONVERTIBLE DEBENTURES LISTED AS LSL.DB

LSL PHARMA GROUP ANNOUNCES CHANGE OF AUDITORS AND GRANT OF OPTIONS

LSL Pharma Group Second Quarter 2024 Earnings: CA$0.007 loss per share (vs CA$0.038 loss in 2Q 2023)

LSL PHARMA GROUP REPORTS RECORD REVENUES FOR THE SECOND QUARTER 2024

LSL Pharma Group Announces Closing of Second and Final Tranche of Private Placement and Closing of Units for Debt

LSL Pharma Group Announces Voting Results of Its Annual and Special Meeting of Shareholders

LSL Pharma Group Secures $1.5 Million as the First Closing of Its Non-Brokered Private Placement

LSL Pharma Group Completes the Acquisition of Virage Santé

LSL Pharma Group Announces Engagement of Red Cloud Securities

LSL Pharma Group Announces a Combination of Private Placements for Maximum Aggregate Gross Proceeds of $4.5 Million

Performance Overview